UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.2033-2046

2014

Volltextzugriff (PDF)

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Clinical pharmacokinetics, 2016-05, Vol.55 (5), p.605-613

2016

Volltextzugriff (PDF)

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa

Bioorganic & medicinal chemistry letters, 2019-08, Vol.29 (16), p.2415-2427

2019

Volltextzugriff (PDF)

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

CPT: pharmacometrics and systems pharmacology, 2023-06, Vol.12 (6), p.853-864

2023

Volltextzugriff (PDF)

Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

Journal of medicinal chemistry, 2016-08, Vol.59 (16), p.7696-7696

2016

Volltextzugriff (PDF)

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The New England journal of medicine, 2021-11, Vol.385 (21), p.1941-1950

2021

Volltextzugriff (PDF)

The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection

Drug metabolism and disposition, 2018-08, Vol.46 (8), p.1212-1225

2018

Volltextzugriff (PDF)

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical infectious diseases, 2017-07, Vol.65 (1), p.6-12

2017

Volltextzugriff (PDF)

SAT462 - Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers

Journal of hepatology, 2020-08, Vol.73, p.S885-S885

2020

Volltextzugriff (PDF)

Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers

Journal of hepatology, 2020-08, Vol.73, p.S885

2020

Volltextzugriff (PDF)

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0127323-e0127323

2024

Volltextzugriff (PDF)

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Clinical infectious diseases, 2018-08, Vol.67 (6), p.934-940

2018

Volltextzugriff (PDF)

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

American journal of health-system pharmacy, 2005-11, Vol.62 (21), p.2271-2277

2005

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial

Annals of internal medicine, 2015-12, Vol.163 (11), p.809-817

2015

Volltextzugriff (PDF)

Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

Drugs in R&D, 2021-12, Vol.21 (4), p.455-465

2021

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

Clinical pharmacokinetics, 2018-11, Vol.57 (11), p.1449-1457

2018

Volltextzugriff (PDF)

631. Preliminary safety and pharmacokinetic profile of VIR-2482: a monoclonal antibody for the prevention of influenza A illness

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S376-S376

2020

Volltextzugriff (PDF)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Open forum infectious diseases, 2023-08, Vol.10 (8), p.ofad354-ofad354

2023

Volltextzugriff (PDF)

Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs

Molecular pharmaceutics, 2015-09, Vol.12 (9), p.3455-3467

2015

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C

Antiviral therapy, 2015-01, Vol.20 (7), p.699-708

2015

Volltextzugriff (PDF)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S353-S354

2021

Volltextzugriff (PDF)

Antibody therapy reverses biological signatures of COVID-19 progression

Cell reports. Medicine, 2022-08, Vol.3 (8), p.100721-100721, Article 100721

2022

Volltextzugriff (PDF)

Accounting for the Effects of Moderately Increased Pressure on the Energetics of Melting and Solubility in Metered Dose Inhalers

Drug development and industrial pharmacy, 2008-01, Vol.34 (9), p.930-935

2008

Volltextzugriff (PDF)

Accounting for the Effects of Moderately Increased Pressure on the Energetics of Melting and Solubility in Metered Dose Inhalers: Innovative Inhalation Technologies

Drug development and industrial pharmacy, 2008, Vol.34 (9), p.930-935

2008

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(33)
Dissertationen
(2)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Pharmacology & Pharmacy
(18)
Humans
(11)
Male
(8)
Female
(7)
Metered Dose Inhalers
(7)
Adult
(6)
Biological And Medical Sciences
(6)
Chemistry, Medicinal
(6)
General Pharmacology
(6)
Medical Sciences
(6)
Middle Aged
(6)
Pharmaceutical Technology. Pharmaceutical Industry
(6)
Pharmacology. Drug Treatments
(6)
Animals
(5)
Antiviral Agents - Adverse Effects
(5)
Antiviral Agents - Therapeutic Use
(5)
Microbiology
(5)
Particle Size
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

SAT462 - Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers

Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial

Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

631. Preliminary safety and pharmacokinetic profile of VIR-2482: a monoclonal antibody for the prevention of influenza A illness

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs

Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Antibody therapy reverses biological signatures of COVID-19 progression

Accounting for the Effects of Moderately Increased Pressure on the Energetics of Melting and Solubility in Metered Dose Inhalers

Accounting for the Effects of Moderately Increased Pressure on the Energetics of Melting and Solubility in Metered Dose Inhalers: Innovative Inhalation Technologies

Suchergebnisse filtern